Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
12.8177
Open
11.850
VWAP
12.22
Vol
41.76K
Mkt Cap
177.47M
Low
11.840
Amount
510.26K
EV/EBITDA(TTM)
--
Total Shares
14.48M
EV
24.88M
EV/OCF(TTM)
--
P/S(TTM)
1.54K
Inhibrx, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of biologic therapeutic candidates in oncology and orphan diseases. Its clinical pipeline includes therapeutic candidates, such as INBRX-101, INBRX-109, INBRX-105 and INBRX-106. INBRX-101 is an engineered recombinant human alpha-1 antitrypsin fragment crystallizable (AAT-Fc) fusion protein therapeutic candidate that the Company is developing for the treatment of patients with Alpha-1 Antitrypsin Deficiency (AATD) and acute Graft-versus -host-disease (aGvHD). INBRX-109 is an engineered tetravalent therapeutic candidate targeting death-receptor 5 (DR5), a TNFRSF member, also known as tumor necrosis factor-related apoptosis-inducing ligand or TRAIL receptor 2. INBRX-105 is a conditional tetravelent PD-L1 targeted 4-1BB agonist that is being investigated as a single agent and in combination with Keytruda in patients with locally advanced or metastatic solid tumors.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q1
FY2024Q4
--
--
-3.120
+116.67%
--
--
-2.885
+66.76%
Estimates Revision
The market is revising No Change the revenue expectations for Inhibrx, Inc. (INBX) for FY2024, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 0.16%.
Revenue Estimates for FY2024
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2024
No Change
0.00%
In Past 3 Month
Stock Price
Go Up
+0.16%
In Past 3 Month
Valuation Metrics
The current forward P/E ratio for Inhibrx Inc (INBX.O) is -0.96, compared to its 5-year average forward P/E of -0.42. For a more detailed relative valuation and DCF analysis to assess Inhibrx Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-0.42
Current PE
-0.96
Overvalued PE
0.22
Undervalued PE
-1.06
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2024Q4
YoY :
-93.88%
100.00K
Total Revenue
FY2024Q4
YoY :
-43.45%
-49.93M
Operating Profit
FY2024Q4
YoY :
-47.96%
-47.87M
Net Income after Tax
FY2024Q4
YoY :
+78.61%
-3.09
EPS - Diluted
FY2024Q4
YoY :
-27.42%
-43.74M
Free Cash Flow
FY2024Q4
YoY :
0.00%
100.00
Gross Profit Margin - %
FY2024Q4
YoY :
+795.92%
-98.50K
FCF Margin - %
FY2024Q4
YoY :
+735.56%
-47.87K
Net Margin - %
FY2024Q4
885.84
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
10.3M
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
2
1.5M
USD
Months
6-9
16
3.8M
USD
Months
0-12
1
997.0K
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
8.9K
Volume
1
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
6
3.0M
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
10.3M
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
2
1.5M
USD
Months
6-9
16
3.8M
USD
Months
0-12
1
997.0K
USD
Months
INBX News & Events
Events Timeline
2025-04-01 (ET)
2025-04-01
16:07:51
Inhibrx appoint Carlos Bais as Chief Scientific Officer
2025-03-17 (ET)
2025-03-17
16:07:09
Inhibrx reports Q4 EPS ($3.09) vs. ($6.93) last year
2025-01-21 (ET)
2025-01-21
16:05:40
Inhibrx announces preliminary ozekibart data, initiates new expansion cohort
Sign Up For More Events
Sign Up For More Events
News
5.0
04-01NewsfilterInhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President
4.0
03-18BenzingaCitizens Capital Markets Reiterates Market Perform on Inhibrx Biosciencesto Market Perform
4.0
03-18Business InsiderJMP Securities Remains a Hold on Inhibrx Biosciences Inc (INBX)
Sign Up For More News
People Also Watch
QD
Qudian Inc
2.650
USD
0.00%
HNRG
Hallador Energy Co
14.690
USD
-1.57%
CMTG
Claros Mortgage Trust Inc
2.430
USD
+0.83%
OMER
Omeros Corp
7.310
USD
+0.14%
VZLA
Vizsla Silver Corp
2.170
USD
-2.25%
OPAL
Opal Fuels Inc
1.740
USD
+16.78%
WLDN
Willdan Group Inc
38.390
USD
+0.44%
CASS
Cass Information Systems Inc
40.570
USD
-1.19%
LASR
nLIGHT Inc
7.820
USD
+0.90%
KULR
KULR Technology Group Inc
1.350
USD
+2.27%
FAQ
What is Inhibrx Inc (INBX) stock price today?
The current price of INBX is 12.26 USD — it has increased 2.34 % in the last trading day.
What is Inhibrx Inc (INBX)'s business?
What is the price predicton of INBX Stock?
What is Inhibrx Inc (INBX)'s revenue for the last quarter?
What is Inhibrx Inc (INBX)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Inhibrx Inc (INBX)'s fundamentals?
How many employees does Inhibrx Inc (INBX). have?